From Statistical Significance to Strategic Value

Why Clinical Success Does Not Guarantee Program Continuation

Executive Summary

In drug development, failure is visible and success is assumed to be decisive. But across biotech and pharmaceutical portfolios, a growing category of assets enters an in-between state of positive but unusable. In this state, the study meets its primary endpoint and regulators accept the data; yet, the program stalls, loses investment priority, or fails commercially.

Modern development programs prioritize answering regulatory questions, and strategic ones are treated as an afterthought. Trials demonstrate statistical efficacy without establishing adoption, differentiation, or treatment positioning.

The consequences:

• Phase II success that does not justify Phase III

• Phase III success that does not justify launch scale

• Approval without uptake

• Assets licensed below expected value

• Programs discontinued regardless of positive data

  
  

This paper examines why this occurs and introduces a decision-oriented development framework that aligns clinical evidence with real-world adoption decisions.

---

The Industry’s Implicit Model

Clinical development is structured around a binary:

Demonstrate efficacy → Value emerges

This assumption historically held when:

• Mechanisms were clear

• Treatment lines were limited

• Clinical pathways were stable

• Physicians adopted mechanistically

Modern medicine has changed and physicians now adopt comparatively, payers adopt economically, and guidelines adopt behaviorally. In other words, a drug can work and still have no place in real-world application.

The Rise of the “Positive Failure”

A new category now appears across portfolios:

Statistically successful programs that fail strategic continuation.

Common outcomes:

• Indication narrowing after Phase II

• Post-Phase III deprioritization

• Approval with restricted reimbursement

• Weak market penetration

• Licensing below modeled valuation

These programs are solid scientifically but fail to create a treatment decision.

What Trials Currently Demonstrate

Most studies are designed to answer if the drug performs better than placebo, but stakeholders have different questions.

Stakeholder	Question
Physician	When would I switch a patient to this?
Payer	Why should I fund this instead of alternatives?
Guideline body	Where does this sit in the pathway?
Investor	Does this expand or fragment the market?

A trial can be perfectly positive and still answer none of these.

The Evidence Misalignment

• Comparator Neutrality

  • Placebo-controlled success does not imply therapeutic positioning.

• Endpoint Non-Transferability

  • Statistical endpoints do not map to treatment decisions.

• Population Ambiguity

  • Broad inclusion increases significance but decreases adoption clarity.

• Economic Blindness

  • Clinical relevance without cost relevance blocks reimbursement.

• Behavioral Ignorance

  • Switching behavior is not inferred from efficacy magnitude.

The study answers science. The market requires context.

The Cost

When trials do not create positioning clarity:

• Phase III becomes a strategic gamble

• Label discussions become restrictive

• Pricing power collapses

• Market education cost inflates

• Commercial teams claim narratives unsupported by data

At this point, additional trials cannot fix the problem, because the wrong evidence was generated.

A Decision-Oriented Development Model

Maxeome frames development around a different objective:

A trial must justify a real-world treatment decision, not just a statistical conclusion.

We refer to this as Decision-Capable Evidence.

Core Principles

• Position Before Proof

  • Define where the drug fits before proving it works.

• Comparator Intentionality

  • Comparator choice determines adoption logic.

• Endpoint Translation

  • Endpoints must map to physician action.

• Population Precision

  • Trials must identify users, not average patients.

• Economic Visibility

  • Clinical outcomes must anticipate reimbursement logic.

What Changes When Evidence Is Decision-Capable

The traditional model involves generating a positive result, interpreting it, and creating the strategy. On the other hand, the decision-oriented model defines the strategy first, generates the evidence, then immediately utilizing it.

Implications for Sponsors

• For Biotech: Expands clinical trials from efficacy studies to proof of investability.

• For Pharma: Prevents expensive Phase III programs lacking commercial rationale.

• For Investors: Improves valuation confidence after data release.

• For Partnerships: Enables licensing negotiations based on position rather than speculation..

  
  

Conclusion

The industry has spent decades improving the probability that a trial shows efficacy, but spent far less effort ensuring that efficacy answers a decision. As therapeutic landscapes grow crowded, statistical success alone no longer advances a drug. Programs no longer fail because drugs do not work, they fail because data does not guide action.

About Maxeome

Maxeome supports biotechs and pharmaceutical companies in designing development strategies that produce decision-capable evidence. We ensure that when a trial succeeds, the program moves forward.